NCT01038739View on ClinicalTrials.gov

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

PHASE3TerminatedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Diverticulitis
Interventions
DRUG

Mesalazine

3 g per day

DRUG

Mesalazine

1.5 g per day

DRUG

Placebo

0 g per day

Trial Locations (1)

32168

United Medical Research, New Smyrna Beach

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY